Memphasys Secures Additional Order for Fertility Device System in Japan; Shares Jump 9%

Memphasys (ASX:MEM) secured an order for its Felix fertility device system with Vitrolife Japan, a subsidiary of Swedish medical distributor Vitrolife Group, according to a filing with the Australian

MT NewswiresMar 18 09:38

Memphasys Completes Trial of Animal Fertility System

Memphasys (ASX:MEM) completed a field trial of its artificial insemination port system consisting of four bulls and 146 cows at a stud farm in New South Wales. The system was able to reach 60% of the

MT NewswiresJan 26 13:34

Memphasys' Entitlement Offer Undersubscribed

Memphasys' (ASX:MEM) non-renounceable entitlement offer incurred a shortfall of 158.9 million rights, the reproductive biotechnology firm said on Friday. Of the 213.2 million rights offered, only 54.3

MT NewswiresJan 12 12:32

Memphasys Accelerates Commercial Approval for Sperm-separation Device

Despite innovative technology, Memphasys (ASX:MEM) has been swimming against the tide in recent times. But with the company poised to bank $4.23 million in a capital raising and having signed expanded

sharecafeJan 10 14:03

Memphasys Signs Distribution Deals for Fertility System; Shares Jump 8%

Memphasys (ASX:MEM) signed a deal with subsidiaries of Swedish in vitro fertilization firm Vitrolife to distribute the Felix reproductive system in the markets of Canada and New Zealand. First orders

MT NewswiresJan 2 10:51

Memphasys Receives AU$1.3 Million R&D Tax Rebate

Memphasys (ASX:MEM) received a research and development tax refund of about AU$1.3 million. The tax rebate will be used to repay an R&D loan to Radium Capital and to fund the continued development and

MT NewswiresOct 25, 2023 12:13